Appropriateness of the prescriptions of conventional versus new oral anticoagulants at discharge from a department of internal medicine

被引:3
作者
Bochatay, L. [1 ]
Beney, J. [1 ]
Jordan-von Gunten, V. [1 ]
Petignat, P. A. [2 ]
Roulet, L. [1 ]
机构
[1] Hop Valais, Inst Cent ICHV, Serv Pharm, Ave Grand Champsec 86, CH-1951 Sion, Switzerland
[2] Hop Valais, Serv Med Interne, Ave Grand Champsec 86, CH-1951 Sion, Switzerland
来源
REVUE DE MEDECINE INTERNE | 2016年 / 37卷 / 09期
关键词
Oral anticoagulants; Acenocoumarol; Dabigatran; Rivaroxaban; NONVALVULAR ATRIAL-FIBRILLATION; ADVERSE DRUG-REACTIONS; ANTITHROMBOTIC THERAPY; WARFARIN USE; RISK; CARE; DABIGATRAN; PATIENT; STROKE; ACENOCOUMAROL;
D O I
10.1016/j.revmed.2015.10.355
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background. - The recently introduced oral direct anticoagulants (ODAs), presumably safer, and with comparable efficacy to the vitamin K antagonists (VKAs), may reshape the world of anticoagulation medicine. This study aimed to assess the prescription appropriateness of ODAs and VKAs at discharge from hospital. Methods. - We performed a one year retrospective study between August 2012 and July 2013 in the department of internal medicine of a regional hospital (HVs Sion) using Electronic Medical Records. All patients receiving an ODA were included and matched to a patient treated with a VKA. The appropriateness of prescription at discharge was defined by an adequate indication and dosing, the absence of contraindication, a minimal risk of drug-drug interactions and no major bleeding or venous thromboembolism during the hospitalization. The bleeding risk was evaluated with the HAS-BLED score when the indication was atrial fibrillation (AF). Results. - Out of the 44 patients included (22 with an ODA and 22 with a VILA), 38 received an appropriate prescription according to all criteria. Two patients had an inadequate dosing. A potential drug-drug interaction was detected in 3 patients receiving a VKA and in 1 patient receiving an ODA. No major contraindication was found, but a relative contraindication was discussed in 3 cases. The majority of patients receiving an ODA for an AF had a minor bleeding risk. Conclusion. - No significant difference was ascertained between the two groups regarding the appropriateness of prescription. Our results suggest that ODAs were cautiously used in our setting. (C) 2015 Societe Nationale Francaise de Medecine Interne (SNFMI). Published by Elsevier Masson SAS. All rights reserved.
引用
收藏
页码:579 / 586
页数:8
相关论文
共 42 条
[31]   Anticoagulant treatment of patients with chronic atrial fibrillation in primary health care in Sweden -: a retrospective study of incidence and quality in a registered population [J].
Nilsson, GH ;
Björholt, I ;
Krakau, I .
FAMILY PRACTICE, 2004, 21 (06) :612-616
[32]   Frequency of adverse events in patients with poor anticoagulation: a meta-analysis [J].
Oake, Natalie ;
Fergusson, Dean A. ;
Forster, Alan J. ;
van Walraven, Carl .
CANADIAN MEDICAL ASSOCIATION JOURNAL, 2007, 176 (11) :1589-1594
[33]   Rivaroxaban versus Warfarin in Nonvalvular Atrial Fibrillation [J].
Patel, Manesh R. ;
Mahaffey, Kenneth W. ;
Garg, Jyotsna ;
Pan, Guohua ;
Singer, Daniel E. ;
Hacke, Werner ;
Breithardt, Guenter ;
Halperin, Jonathan L. ;
Hankey, Graeme J. ;
Piccini, Jonathan P. ;
Becker, Richard C. ;
Nessel, Christopher C. ;
Paolini, John F. ;
Berkowitz, Scott D. ;
Fox, Keith A. A. ;
Califf, Robert M. .
NEW ENGLAND JOURNAL OF MEDICINE, 2011, 365 (10) :883-891
[34]   A Novel User-Friendly Score (HAS-BLED) To Assess 1-Year Risk of Major Bleeding in Patients With Atrial Fibrillation The Euro Head Survey [J].
Pisters, Ron ;
Lane, Deirdre A. ;
Nieuwlaat, Robby ;
de Vos, Cees B. ;
Crijns, Harry J. G. M. ;
Lip, Gregory Y. H. .
CHEST, 2010, 138 (05) :1093-1100
[35]   Admissions to hospital caused by adverse drug reactions:: cross sectional incidence study [J].
Pouyanne, P ;
Haramburu, F ;
Imbs, JL ;
Bégaud, B .
BRITISH MEDICAL JOURNAL, 2000, 320 (7241) :1036-1036
[36]   Evaluation of antithrombotic usage for atrial fibrillation in aged care facilities [J].
Singh, P. ;
Arrevad, P. S. ;
Peterson, G. M. ;
Bereznicki, L. R. .
JOURNAL OF CLINICAL PHARMACY AND THERAPEUTICS, 2011, 36 (02) :166-171
[37]   Rivaroxaban: Practical Considerations for Ensuring Safety and Efficacy [J].
Smythe, Maureen A. ;
Fanikos, John ;
Gulseth, Michael P. ;
Wittkowsky, Ann K. ;
Spinler, Sarah A. ;
Dager, William E. ;
Nutescu, Edith A. .
PHARMACOTHERAPY, 2013, 33 (11) :1223-1245
[38]   Effect of study setting on anticoagulation control - A systematic review and metaregression [J].
van Walraven, Carl ;
Jennings, Alison ;
Oake, Natalie ;
Fergusson, Dean ;
Forster, Alan J. .
CHEST, 2006, 129 (05) :1155-1166
[39]   Stroke prevention in atrial fibrillation: physicians' attitudes to anticoagulation in older people [J].
Vasishta, S ;
Toor, F ;
Johansen, A ;
Hasan, M .
ARCHIVES OF GERONTOLOGY AND GERIATRICS, 2001, 33 (03) :219-226
[40]   Anticoagulation in atrial fibrillation in the elderly: The geriatrician point of view with a focus on the direct oral anticoagulants [J].
Vogel, T. ;
Geny, B. ;
Kaltenbach, G. ;
Lang, P. -O. .
REVUE DE MEDECINE INTERNE, 2015, 36 (01) :22-30